CUHK_CCT00119
2007-09-11
Retrospective
N/A
Departmental
Department of Paediatrics, The Chinese University of Hong Kong
N/A
Albert Martin Li
Department of Paediatrics, PWH, Shatin, Hong Kong
Telephone #: 26322859; Fax #: 26360020;
email: albertm68mcli@yahoo.com
Albert Martin Li
Department of Paediatrics, PWH, Shatin, Hong Kong
Telephone #: 26322859; Fax #: 26360020;
email: albertm68mcli@yahoo.com
Nasal Corticosteroids as Treatment for Childhood Obstructive Sleep Apnoea.
N/A
Yes
2004-03-02
Childhood Obstructive Sleep Apnoea
Drug
Nasonex
4 months
Placebo. The appearance and smell of the corticosteroids and placebo are indistinguishable.
Inclusion criteria: Once the subjects have completed the overnight PSG, they will be invited to participate in this current study if they satisfied the followings: (1) Confirmed OSAS with a respiratory disturbance index (RDI) of between 1 and 10. It is our current practice to offer children with moderate-severe OSAS (RDI > 10) surgical intervention in the form of adeno-tonsillectomy. (2) Informed consent obtained from parents.
Exclusion criteria: (1) Children with genetic syndromes, congenital or acquired neurological diseases, neuromuscular diseases, and those who have had previous upper airway surgery. (2) Children with fixed nasal obstruction such as previous nasal fracture or deviated nasal septum.
Randomized
Placebo
Double-blind
Parallel
2006-05-27
52
Recruiting
The primary outcome is the change from baseline the various respiratory parameters as documented by overnight polysomnography after a 4-month treatment.
The secondary outcome is the change from baseline the adenoidal size as assessed by standardized lateral neck radiograph after a 4-month treatment.
2011-04-04
Yes
N/A
|
|
|
|
|
---|---|---|---|---|
No documents yet. |